Stockreport

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value [Yahoo! Finance]

Theravance Biopharma, Inc. - Ordinary Shares  (TBPH) 
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.theravance.com/investor-relations
PDF YUPELRI ® (revefenacin) net sales of $62.2 million , recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 CYPRESS enrollment in [Read more]